VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​de

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “C

Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cry

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

Zymeworks is transitioning into an oncology royalty platform with a robust internal discovery engine

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biote

Zymeworks NASDAQ: ZYME reported a wider first-quarter loss as revenue declined from year-earlier mil

Zymeworks Inc. (ZYME) Q1 2026 Earnings Call Transcript

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus E

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Applicatio

Zymeworks (NASDAQ: ZYME - Get Free Report) and ADVANZ PHARMA (OTCMKTS:CXRXF - Get Free Report) are b

Zymeworks (NASDAQ: ZYME) used a presentation at the Bloom Burton conference to outline how the compa

Shares of Zymeworks Inc. (NASDAQ: ZYME - Get Free Report) have been assigned an average recommendati

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

  During Thursday, 849 stocks hit new 52-week lows.

    Tuesday's session saw 729 companies set new 52-week lows.

Stocks That Hit 52-Week Highs On Tuesday

Stocks That Hit 52-Week Highs On Monday

Stocks That Hit 52-Week Highs On Friday